RICHMOND, Va., July 20, 2026
Virginia’s Advanced Pharmaceutical Manufacturing (APM) Tech Hub has secured a $15.97 million investment from the U.S. Economic Development Administration (EDA) to launch the End-to-End (E2E) Commercialization Project, a major initiative designed to strengthen the United States’ domestic pharmaceutical manufacturing ecosystem. Announced by the Alliance for Building Better Medicine, the project brings together Civica, Inc. (Civica Rx), Phlow Corp., Occam Systems, and more than 55 public and private partners to establish an integrated commercialization pathway that connects domestically sourced key starting materials (KSMs), active pharmaceutical ingredients (APIs), finished dose manufacturing, regulatory approval, and medicine delivery to patients. The initiative represents a significant step toward creating a resilient, end-to-end U.S. pharmaceutical supply chain capable of reducing dependence on overseas manufacturing while improving national preparedness, innovation, and access to essential medicines.
Integrated U.S. Manufacturing Ecosystem Strengthens Medicine Supply
The End-to-End Commercialization Project has been designed to establish a seamless domestic pharmaceutical production network by integrating every stage of medicine development and commercialization. Occam Systems will accelerate the development of domestically sourced key starting materials, Phlow Corp. will expand U.S.-based active pharmaceutical ingredient (API) manufacturing, and Civica Rx will oversee finished dose formulation, FDA regulatory approval, commercial-scale manufacturing, and nationwide distribution. The first phase of the initiative will focus on producing four critical sterile injectable medicines—ketamine, midazolam, norepinephrine, and succinylcholine—which are widely used in emergency medicine, anesthesia, and critical care. By connecting raw material production with commercial manufacturing through a fully domestic pathway, the project aims to improve supply chain resilience, reduce medicine shortages, and strengthen the nation’s ability to respond to healthcare emergencies while ensuring reliable patient access to essential therapies.
Public-Private Collaboration Drives Pharmaceutical Innovation
The new federal investment builds upon more than $1.7 billion in previous federal, state, philanthropic, and private funding that helped establish Virginia’s Advanced Pharmaceutical Manufacturing Tech Hub as one of the country’s leading centers for pharmaceutical innovation. Since its launch, the Alliance for Building Better Medicine has united industry leaders, academic institutions, government agencies, workforce organizations, nonprofit groups, and economic development partners to advance domestic pharmaceutical manufacturing capabilities. The initiative has already secured multiple national awards supporting workforce development, manufacturing infrastructure, research, and commercialization. The Commonwealth Center for Advanced Manufacturing (CCAM) continues to provide operational leadership for the Alliance, helping coordinate collaborative projects that strengthen America’s pharmaceutical manufacturing competitiveness while supporting regional economic growth and workforce development.
Advertisement
Federal Investment Supports Long-Term Pharmaceutical Security
The latest EDA investment reinforces the United States’ broader strategy to restore domestic pharmaceutical manufacturing capacity following decades of increasing reliance on complex global supply chains. With more than 130 million Americans depending on medicines produced through international manufacturing networks, persistent shortages and supply chain disruptions have highlighted the need for greater domestic production capabilities. Virginia’s growing pharmaceutical ecosystem has also attracted significant private investment, including major manufacturing commitments from AstraZeneca, Eli Lilly, and Merck, further strengthening the region’s position as a national hub for advanced pharmaceutical manufacturing. By integrating innovation, manufacturing, commercialization, workforce development, and regulatory readiness, the End-to-End Commercialization Project is expected to accelerate the production of essential medicines while improving national health security, supporting high-value jobs, and advancing the future of pharmaceutical manufacturing in the United States.
Source: Alliance for Building Better Medicine Press release
